Magnetar Financial LLC Boosts Stock Position in LivaNova PLC (NASDAQ:LIVN)

Magnetar Financial LLC grew its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 8.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 814,452 shares of the company’s stock after purchasing an additional 61,114 shares during the quarter. Magnetar Financial LLC owned approximately 1.50% of LivaNova worth $44,648,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LIVN. New York State Teachers Retirement System grew its position in shares of LivaNova by 0.3% during the 1st quarter. New York State Teachers Retirement System now owns 64,322 shares of the company’s stock valued at $3,598,000 after acquiring an additional 200 shares during the period. Arizona State Retirement System raised its stake in shares of LivaNova by 2.0% in the second quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock valued at $828,000 after buying an additional 299 shares during the period. State of Michigan Retirement System lifted its position in shares of LivaNova by 2.3% during the 1st quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock valued at $739,000 after buying an additional 300 shares during the last quarter. Fifth Third Bancorp raised its stake in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after acquiring an additional 332 shares during the period. Finally, Hexagon Capital Partners LLC raised its stake in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after acquiring an additional 370 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

LIVN has been the subject of a number of research reports. Robert W. Baird upgraded shares of LivaNova from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $55.00 to $66.00 in a research report on Tuesday, September 17th. Needham & Company LLC raised their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Stifel Nicolaus boosted their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $70.80.

LivaNova Stock Down 0.9 %

Shares of LIVN opened at $50.75 on Monday. LivaNova PLC has a 1 year low of $42.75 and a 1 year high of $64.47. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94. The stock has a 50 day simple moving average of $48.85 and a two-hundred day simple moving average of $53.38. The firm has a market cap of $2.75 billion, a P/E ratio of -84.58 and a beta of 1.00.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.15. The business had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. On average, analysts forecast that LivaNova PLC will post 2.58 earnings per share for the current fiscal year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.